Summary:Autologous HCT patients often have poor oral intake for 2-4 weeks post transplant. To compare outcomes between patients provided prophylactic total parenteral nutrition (TPN) or an oral diet (OD), 55 well nourished breast cancer/ hematopoietic cell transplantation (HCT) patients were randomized to TPN (n ¼ 27), beginning day À1, or OD (n ¼ 28). Parameters studied include length of stay (LOS), engraftment, infections, survival, weight, anthropometrics, handgrip strength, and quality of life (QOL) In all, 50% of OD patients were given TPN due to poor oral intake for 10 consecutive days. No significant differences were found between the groups for any of the above parameters except weight and anthropometrics, which were better maintained in the TPN group than the OD group. Trends were seen for increased infections, more stable handgrip strength, and improved QOL in the TPN group vs the OD group. Prophylactic TPN did result in a more intact nutritional status and preservation of lean body mass post transplant but did not impact LOS or survival when compared to OD. For this reason, TPN should be reserved for autologous HCT patients with pretransplant nutritional depletion, complications post transplant, or prolonged poor oral intake. These results should not be extrapolated to allogeneic HCT patients but are likely applicable to other well nourished autologous HCT patients. The nutrition problems associated with high-dose chemotherapy and hematopoietic cell transplantation (HCT) are well known. 1-3 Most patients' oral intake is minimal for at least 2-3 weeks post transplant (posttx) and use of total parenteral nutrition (TPN) during this period is common. The preparative regimens utilized at our center typically result in significant pancytopenia and gastrointestinal (GI) toxicities, including mucositis, leading to the intuitive conclusion that TPN is necessary. Weisdorf et al 4 showed that provision of prophylactic TPN was beneficial to marrow transplant recipients. At the time our study was initiated, TPN was a standard of care posttx at our center. However, since HCT for breast cancer (CA) is relatively new, no breast CA patients were included in the aforementioned trial. Also, several advances have been made since that trial was conducted (cytokine growth factors and peripheral blood stem cell transplants), which have shortened the neutropenic period in this patient population, which, in turn, may lead to more rapid return to normal GI function. While currently the use of autologous HCT in breast CA is controversial and not currently carried out at our center, interest in HCT for breast CA still exists. [5][6][7][8] This study was carried out to compare clinical, and nutritional outcomes, as well as sense of well-being and survival, in breast CA patients undergoing HCT randomized to an oral diet vs prophylactic TPN.
Patients and methodsA total of 55 females with stage II-IV breast CA undergoing high-dose chemotherapy and HCT were prospectively randomized to an oral diet (OD) (n ¼ 28) or TPN (n ¼ 27). Inst...